Executive Vice President and Chief Operating Officer at ESSA Pharma - Vancouver, British Columbia, Canada
Executive Director, preclinical development and translational medicine
ESSA is a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer. ESSA's lead clinical candidate, EPI-7386, represents a new approach to disrupting androgen receptor signaling pathway, the primary driver of prostate cancer growth.